BIOGEN INC (IDP.DE) Stock Fundamental Analysis
FRA:IDP - US09062X1037 - Common Stock
113.5 EUR
-1.5 (-1.3%)
Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 73 industry peers in the Biotechnology industry. While IDP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. IDP has a bad growth rate and is valued cheaply. These ratings could make IDP a good candidate for value investing.
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
In the past 5 years IDP has always been profitable.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 5.40%, IDP belongs to the best of the industry, outperforming 80.82% of the companies in the same industry.
With an excellent Return On Equity value of 8.68%, IDP belongs to the best of the industry, outperforming 82.19% of the companies in the same industry.
With an excellent Return On Invested Capital value of 9.52%, IDP belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for IDP is below the industry average of 13.68%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROIC | 9.52% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
The Profit Margin of IDP (15.31%) is better than 84.93% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
Looking at the Operating Margin, with a value of 27.35%, IDP belongs to the top of the industry, outperforming 84.93% of the companies in the same industry.
In the last couple of years the Operating Margin of IDP has declined.
IDP's Gross Margin of 75.43% is fine compared to the rest of the industry. IDP outperforms 68.49% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
IDP has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.97 indicates that IDP is not a great score, but indicates only limited risk for bankruptcy at the moment.
IDP's Altman-Z score of 2.97 is fine compared to the rest of the industry. IDP outperforms 71.23% of its industry peers.
The Debt to FCF ratio of IDP is 3.40, which is a good value as it means it would take IDP, 3.40 years of fcf income to pay off all of its debts.
IDP has a Debt to FCF ratio of 3.40. This is amongst the best in the industry. IDP outperforms 83.56% of its industry peers.
A Debt/Equity ratio of 0.36 indicates that IDP is not too dependend on debt financing.
IDP has a Debt to Equity ratio (0.36) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Altman-Z | 2.97 |
ROIC/WACC1.03
WACC9.22%
2.3 Liquidity
IDP has a Current Ratio of 2.50. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
IDP has a Current ratio (2.50) which is comparable to the rest of the industry.
A Quick Ratio of 1.79 indicates that IDP should not have too much problems paying its short term obligations.
IDP has a Quick ratio (1.79) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
The earnings per share for IDP have decreased by -3.61% in the last year.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 3.36%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
3.2 Future
Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 1.24% on average per year.
IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.36% yearly.
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.24%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.36%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.28, which indicates a very decent valuation of IDP.
Compared to the rest of the industry, the Price/Earnings ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 93.15% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.08, IDP is valued rather cheaply.
The Price/Forward Earnings ratio is 8.22, which indicates a very decent valuation of IDP.
Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 93.15% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.72, IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.28 | ||
| Fwd PE | 8.22 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 90.41% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 91.78% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.52 | ||
| EV/EBITDA | 6.67 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (8/29/2025, 7:00:00 PM)
113.5
-1.5 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.67%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap16.64B
Analysts72.09
Price Target146.46 (29.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.1%
Min EPS beat(2)17.28%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)15.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)13.06%
EPS beat(12)12
Avg EPS beat(12)11.49%
EPS beat(16)14
Avg EPS beat(16)10.96%
Revenue beat(2)2
Avg Revenue beat(2)9.15%
Min Revenue beat(2)6.67%
Max Revenue beat(2)11.62%
Revenue beat(4)3
Avg Revenue beat(4)4.43%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)1.84%
Revenue beat(12)8
Avg Revenue beat(12)1.78%
Revenue beat(16)11
Avg Revenue beat(16)1.73%
PT rev (1m)-4.19%
PT rev (3m)-5.54%
EPS NQ rev (1m)-2.84%
EPS NQ rev (3m)-5.67%
EPS NY rev (1m)6.04%
EPS NY rev (3m)5.87%
Revenue NQ rev (1m)2.72%
Revenue NQ rev (3m)1.92%
Revenue NY rev (1m)4.42%
Revenue NY rev (3m)4.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.28 | ||
| Fwd PE | 8.22 | ||
| P/S | 1.94 | ||
| P/FCF | 10.52 | ||
| P/OCF | 9.18 | ||
| P/B | 1.1 | ||
| P/tB | 11.61 | ||
| EV/EBITDA | 6.67 |
EPS(TTM)13.71
EY12.08%
EPS(NY)13.8
Fwd EY12.16%
FCF(TTM)10.79
FCFY9.5%
OCF(TTM)12.37
OCFY10.89%
SpS58.4
BVpS103.01
TBVpS9.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.4% | ||
| ROE | 8.68% | ||
| ROCE | 10.87% | ||
| ROIC | 9.52% | ||
| ROICexc | 10.7% | ||
| ROICexgc | 37.26% | ||
| OM | 27.35% | ||
| PM (TTM) | 15.31% | ||
| GM | 75.43% | ||
| FCFM | 18.47% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | 3.4 | ||
| Debt/EBITDA | 1.81 | ||
| Cap/Depr | 36.28% | ||
| Cap/Sales | 2.7% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 60.86% | ||
| Profit Quality | 120.66% | ||
| Current Ratio | 2.5 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 2.97 |
F-Score6
WACC9.22%
ROIC/WACC1.03
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.61%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%3.6%
EPS Next Y-1.7%
EPS Next 2Y-1.08%
EPS Next 3Y0.58%
EPS Next 5Y1.24%
Revenue 1Y (TTM)3.36%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%7.33%
Revenue Next Year0.4%
Revenue Next 2Y-1.84%
Revenue Next 3Y-1.15%
Revenue Next 5Y-0.36%
EBIT growth 1Y23.31%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year9.29%
EBIT Next 3Y4.38%
EBIT Next 5Y5.37%
FCF growth 1Y64.41%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y48.2%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%